VEGFA and Familial prostate cancer: A new phase II clinical trial of patients with recurring prostate cancer treated with or without the VEGF inhibitor Bevacizumab after ADT revealed that ADT combined with Bevacizumab resulted in an increased relapse free survival rate, although modestly, compared to ADT alone [19].